Keliximab
- CAS No.
- 174722-30-6
- Chemical Name:
- Keliximab
- Synonyms
- Idec ce91;Keliximab;Keliximab [inn];Keliximab (anti-CD4);Research Grade Keliximab;Immunoglobulin G 1 (human-macaca monoclonal ce91 gamma1-chain anti-human antigen cd 4), disulfide with human-macaca monoclonal ce91 lambda-chain, dimer;Immunoglobulin G1, anti-(human cd4 (antigen)) (human-macaca monoclonal ce91 gamma1-chain), disulfide with human-macaca monoclonal ce91 lambda-chain, dimer
- CBNumber:
- CB01117516
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 62L6LCF5EU |
Keliximab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0628924 | Keliximab 98.23% | 174722-30-6 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0628924 | Keliximab 98.23% | 174722-30-6 | 5mg | $812 | 2026-06-04 | Buy |
| ChemScene | CS-0628924 | Keliximab 98.23% | 174722-30-6 | 10mg | $1300 | 2026-06-04 | Buy |
| aablocks | AA00AM3S | Keliximab ≥95%(SDS-PAGE&SEC-HPLC) | 174722-30-6 | 1mg | $572 | 2026-05-28 | Buy |
| aablocks | AA00AM3S | Keliximab ≥95%(SDS-PAGE&SEC-HPLC) | 174722-30-6 | 5mg | $1426 | 2026-05-28 | Buy |
Keliximab Chemical Properties,Uses,Production
Uses
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research[1][2].
in vivo
Keliximab (5-125 mg/kg; i.v., once) decreases CD4+ T cells[1].
| Animal Model: | Transgenic mice bearing human CD4 molecules on their T cells[1] |
| Dosage: | 5-125 mg/kg |
| Administration: | Intravenous injection, 5-125 mg/kg, once |
| Result: | Dose-dependently down-modulated CD4 and rapidly declined the number of circulating CD4+ T cells compared with clenoliximab. |
References
[1] Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41. PMID:10734150
[2] Anderson D, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997 Jul;84(1):73-84. DOI:10.1006/clin.1997.4363
Keliximab Preparation Products And Raw materials
Raw materials
Preparation Products
Keliximab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5550 | 58 |
| Atagenix Laboratories | 027-87008169 17762441161 | info@atagenix.com | China | 9997 | 58 |
174722-30-6(Keliximab)Related Search:
1of4
